FDA denies acne amendment
This article was originally published in The Tan Sheet
D'Arcy Skincare's petition to amend the OTC topical acne drug products monograph and affirm the combination of sulfur 10% and salicylic acid 2% as generally recognized safe and effective was rejected by the agency. FDA says it is "unaware of any clinical studies demonstrating that both sulfur and salicylic acid contribute to the overall effectiveness of the combination" and that D'Arcy did not submit any data on effectiveness in its petition. D'Arcy had maintained there were no reported adverse events for its Drying Lotion acne treatment, which contains the combination, following more than 20 years of marketing; the firm also submitted a repeat insult patch test for support of safety and consumer testimonials to prove efficacy...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.